Merger of Cyclo Therapeutics and Applied Molecular Transport
Cyclo Therapeutics, (Cyclo) a clinical stage company focused on developing therapies for rare and neurological diseases with limited treatment options,
Tag: Cyclo Therapeutics
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through
Cyclo Therapeutics Submits IND Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and
Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin
Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol® Cyclo™ for treatment of Niemann-Pick
Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)